The FDC released a second highly critical report of PBMs, which may provide further impetus for legislative action to curb ...

Novo Nordisk's financial strength is evident through its 74% historical average ROIC and 85% gross margin. See why I rate NVO ...

Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.

Eli Lilly said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn's ...

In a live taping of "The Readout LOUD" at #JPM25, Eli Lilly CEO Dave Ricks talks Trump, Medicare's drug price negotiation, ...

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

SEC sues Elon Musk over Twitter purchase, Microsoft says businesses should get quantum ready in 2025, and more news to start ...

Eli Lilly (NYSE:LLY) has received FDA approval for its drug Omvoh, also known as mirikizumab-mrkz, for the treatment of moderately to severely active Crohn's disease in adults. The drug was previously ...

LAS VEGAS, NV, UNITED STATES, January 15, 2025 /EINPresswire / -- The Alopecia Areata market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period.

Spain’s Almirall has announced strategic plans at the 43rd JP Morgan Healthcare Conference based on expected double-digit growth within the dermatological area for Almirall’s psoriasis and atopic ...

GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and ...

The report profiles leading players in the Neurogenomics market including Illumina, Thermo Fisher Scientific, F. Hoffmann-La Roche, Agilent Technologies, MGI Tech Co., QIAGEN, Revvity, Pacific ...